|
Targeting the Microenvironment in MDS: The Final Frontier
|
Jul 2020
|
Frontiers in Pharmacology
|
myelodysplastic syndromes (MDS)
|
|
Beneficial effects of eculizumab regardless of prior transfusions or bone marrow disease: Results of the International PNH Registry
|
Jul 2020
|
European Journal of Haematology
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Kinetics of Pre-Myelodysplastic Syndromes Blood Values Correlate with Disease Risk and Survival
|
Jul 2020
|
Hematological Oncology
|
myelodysplastic syndromes (MDS)
|
|
High-dose Romiplostim Accelerates Hematologic Recovery in Patients With Aplastic Anemia Refractory to Eltrombopag
|
Jul 2020
|
Leukemia
|
aplastic anemia
|
|
Secondary Myelodysplastic Syndrome and Leukemia in Acquired Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria
|
Jul 2020
|
Blood
|
aplastic anemia, myelodysplastic syndromes (MDS), paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Genetics of Progression From MDS to Secondary Leukemia
|
Jul 2020
|
Blood
|
myelodysplastic syndromes (MDS)
|
|
Baseline Clinical Characteristics and Disease Burden in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH): Updated Analysis From the International PNH Registry
|
Jul 2020
|
Annals of Hematology
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Where There's Smoke, There's Fire: Inflammation Drives MDS
|
Jul 2020
|
Trends in immunology
|
myelodysplastic syndromes (MDS)
|
|
Rigosertib in Combination With Azacitidine in Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia: Results of a Phase 1 Study
|
Jul 2020
|
Leukemia Research
|
acute myeloid leukemia (AML), myelodysplastic syndromes (MDS)
|
|
Therapy-related Myelodysplastic Syndromes Deserve Specific Diagnostic Sub-Classification and Risk-Stratification-An Approach to Classification of Patients With t-MDS
|
Jun 2020
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
